Please see our open positions below...

Given our recent Series D Financing of $120M []. Adaptive plans to expand our immunoSEQ platform for research and accelerate the commercialization of clonoSEQ, our first diagnostic assay for monitoring Minimal Residual Disease (“MRD”) in blood-based cancers.

Adaptive Biotechnologies Corp. is a platform-based, diagnostic-driven company that leverages next generation sequencing (“NGS”) to profile T-Cell and B-Cell Receptors (“TCRs” and “BCRs”). This breakthrough enables in-depth characterization of the adaptive immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis, and monitoring of cancer patients.

Adaptive is rapidly expanding its commercial infrastructure to bring its immunosequencing diagnostic applications to market. Adaptive represents "what's next" in NGS content and is looking for the best in brightest across all areas of the organization.

Both leadership and staff positions will become available in the following areas:


If you are interested in exploring opportunities immediately with us in these areas, please apply to one of our open positions, or submit your resume to, noting the area of interest, as listed above, in your cover letter.

When you join Adaptive, you'll be challenged, you'll be inspired, and you'll be proud to be part of a team making a real difference in the lives of us all. No matter what your position is within the company, you'll find a culture that is diverse, fun, team-oriented, and where your bright ideas are truly heard!

Loading Jobs Please Wait...